INVA

Innoviva Inc

INVA, USA

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline), a tetracycline class antibacterial for the treatment of complicated intra-abdominal infections in adults; XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; and ZEVTERA, a cephalosporin antibacterial for the treatment of adult patients with staphylococcus aureus bloodstream infections, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients with community-acquired bacterial pneumonia. Its development pipeline includes Zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

https://www.inva.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
INVA
stock
INVA

Innoviva (NASDAQ: INVA) Lancet Phase 3 gonorrhea data supports zoliflodacin NDA under FDA priority review Stock Titan

Read more →
INVA
stock
INVA

Trading the Move, Not the Narrative: (INVA) Edition news.stocktradersdaily.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$36.4

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

13.37

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Low

1.74

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

8.90 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Medium

6.29 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

45.09 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.42

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 116.89% of the total shares of Innoviva Inc

1.

BlackRock Inc

(14.4657%)

since

2025/06/30

2.

Vanguard Group Inc

(11.3919%)

since

2025/06/30

3.

Renaissance Technologies Corp

(7.5544%)

since

2025/06/30

4.

Dimensional Fund Advisors, Inc.

(6.8142%)

since

2025/06/30

5.

iShares Core S&P Small-Cap ETF

(5.2148%)

since

2025/08/31

6.

Franklin Resources Inc

(4.4873%)

since

2025/06/30

7.

Sarissa Capital Management LP

(4.4684%)

since

2025/06/30

8.

State Street Corp

(3.8994%)

since

2025/06/30

9.

Putnam Global Health Care A

(3.6006%)

since

2025/07/31

10.

American Century Companies Inc

(3.2795%)

since

2025/06/30

11.

Systematic Financial Management LP

(3.2674%)

since

2025/06/30

12.

Millennium Management LLC

(3.1566%)

since

2025/06/30

13.

Vanguard Total Stock Mkt Idx Inv

(3.0621%)

since

2025/07/31

14.

Avantis US Small Cap Value ETF

(2.8865%)

since

2025/08/30

15.

Arrowstreet Capital Limited Partnership

(2.711%)

since

2025/06/30

16.

Morgan Stanley - Brokerage Accounts

(2.5852%)

since

2025/06/30

17.

Bank of America Corp

(2.452%)

since

2025/06/30

18.

iShares Russell 2000 ETF

(2.4164%)

since

2025/08/31

19.

Geode Capital Management, LLC

(2.4161%)

since

2025/06/30

20.

Goldman Sachs Group Inc

(2.3333%)

since

2025/06/30

21.

Vanguard Small Cap Index

(2.2958%)

since

2025/07/31

22.

Citadel Advisors Llc

(2.2822%)

since

2025/06/30

23.

Marshall Wace Asset Management Ltd

(2.1151%)

since

2025/06/30

24.

Royal Bank of Canada

(1.9261%)

since

2025/06/30

25.

Deutsche Bank AG

(1.7274%)

since

2025/06/30

26.

Nuveen, LLC

(1.7025%)

since

2025/06/30

27.

DFA US Small Cap Value I

(1.6867%)

since

2025/07/31

28.

Vanguard Small Cap Value Index Inv

(1.4812%)

since

2025/07/31

29.

Fidelity Small Cap Index

(0.9935%)

since

2025/06/30

30.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9419%)

since

2025/07/31

31.

DFA US Targeted Value I

(0.8743%)

since

2025/07/31

32.

CREF Stock R3

(0.818%)

since

2025/07/31

33.

Dimensional US Targeted Value ETF

(0.8083%)

since

2025/08/29

35.

iShares Russell 2000 Growth ETF

(0.7637%)

since

2025/08/31

36.

Pacer US Small Cap Cash Cows 100 ETF

(0.7328%)

since

2025/08/29

37.

Nuveen Quant Small Cap Equity R6

(0.6944%)

since

2025/07/31

38.

VictoryShares US Sm Md Cp Val Momt ETF

(0.6475%)

since

2025/08/29

39.

Vanguard Tax-Managed Small Cap Adm

(0.6396%)

since

2025/07/31

40.

Invesco Pharmaceuticals ETF

(0.5129%)

since

2025/08/29

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.3846

EPS Estimate

0.4

EPS Difference

-0.0154

Surprise Percent

-3.85%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(8.5)
GARP
Strong GARP(7)
Growth
Moderate Growth(5.5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(3)
Quality
High Quality(8)
Value
Undervalued(7.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.